Dr. John Cush RheumNow
3 years 5 months ago
#RNL2023: Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/YrA7tXMKoI
Cc: @ericdeinmd https://t.co/oXoeZYW7rU
Dr. John Cush RheumNow
3 years 5 months ago
#RNL2023
Kevin Deane: natural history of RA
The onset of RA is a spectrum of disease from genetic/environmental risks; local & systemic autoimmunity (ACPA/RF, mucosal factors); subclinical; unclassified arthralgias; classified RA
When to start treatment? https://t.co/LEsPVQe9QW https://t.co/MbNmxZ39HO
Dr. John Cush RheumNow
3 years 5 months ago
Retrospective study of Calif. Hosp. records on women with SLE (n 2874) and RA (2309) found that Black, Hispanic, and Asian women had 1.3 - 1.5 fold more preterm births than Whites; & blacks had 2-2.4 more PTB than Asian, Hispanic, or Whites. https://t.co/7Nr5KJUNRc https://t.co/3fzTMiM4DG
On the first day of ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. Dr. Petri, a lupus expert from Johns Hopkins Rheumatology, reviewed the latest clinical and animal model studies that offer hope in treatment and gave wide-ranging pearls on a variety of issues that can be faced in this disorder.
Dr. John Cush RheumNow
3 years 5 months ago
Swedish study looked at risk of PsA in psoriasis pts showing PsA risk was significantly higher w/ worsening psoriasis. Incidence of PsA was 1.48/100PY, 3.00, and 5.49/100PY w/ mild, moderate and severe psoriasis. PsA risk was 3.2X higher w/ severe PSO https://t.co/H8QbkRp4d9 https://t.co/Hqlcf3f2bI
Dr. John Cush RheumNow
3 years 5 months ago
Pharma marketing payments to MDs (none; < $100; >$100) correlated with Medicare billing of Intraarticular Hyaluronic Acid injx. In 20 501 MDs, 41.5% gave HA injx; Odds incr w/ payment <$100 (OR 2.06) or >$100 (OR 3.28); 12.7% & 21% more likely https://t.co/BP395xm0TW https://t.co/MDxT8Kl4kq
ACR Convergence 2023, the annual meeting of the American College of Rheumatology (ACR) and the world’s premier rheumatology experience, will be held Nov. 10 – 15 at the San Diego Convention Center in San Diego, CA. This year’s meeting includes the return of an in-person poster hall, five in-person networking lounges, CME for select plenary sessions, and an extra half day of scientific sessions.
Dr. John Cush RheumNow
3 years 5 months ago
Observational study of cannabis use in 25 cancer pts (52% w/ colon/lung/breast CA) taking a 2-wks of ad libitum cannabis noted to have improvements in pain intensity, pain interference, sleep quality, & cognitive function,but no change in quality of life. https://t.co/iZjGMM1Pud https://t.co/vkOWVqfCYi
Dr. John Cush RheumNow
3 years 5 months ago
RheumThoughts: An Opportunity to Say Yes Hi, I am Dr. Kathryn Dao ( @KDAO2011 ) a rheumatologist and senior editor for the RheumNow Women in Rheumatology Campaign. I wanted to share you with an opportunity. An Opportunity to Say Yes. https://t.co/dJKWFAASV9 https://t.co/Cm4vn563Pz
Dr. John Cush RheumNow
3 years 5 months ago
Romania to U.S.: My Journey to a Permanent Residency
One in four practicing physicians in the United States are international medical graduates. I am one of them.
Dr. Maria Danila shares her IMG experience.
https://t.co/vpxyosojxc https://t.co/FrIuLyvgXS
Dr. John Cush RheumNow
3 years 5 months ago
Another review on the annual salaries of different specialists.... https://t.co/bkkcIR5pa5
Dr. John Cush RheumNow
3 years 5 months ago
Full Read comprehensive revie by Isenberg on what Rx work in SLE; they review RCT data on approved drugs and Rx in development:
- Obinutuzumab
- Dapirolizumab
- Deucravacitinib
- Litifilimab
- Atacicept
- Telitacicept https://t.co/jMLlRZuK6e https://t.co/8K0dYLieAH
Dr. John Cush RheumNow
3 years 5 months ago
UK's MHRA has followed EMA final ruling regarding new Safety recs & JAK inhibitors:
- RE: tofacitinib, abrocitinib, baricitinib, upadacitinib & filgotinib use in chr inflammatory Dz.
- avoid JAKi if no suitable alternative: age >=65, smokers, CV/CA Hx https://t.co/Y1vZPHPEPN https://t.co/odovKWebFV
RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis, especially what to do regarding pre-clinical RA.
Dr. Kevin Deane started the discussion by mapping out a very complex course of RA, beginning with a person’s genetic and environmental risk factors. What are Dr. Deane’s recommendations for management of pre-RA patients?
